Truist analyst Jailendra Singh lowered the firm’s price target on Doximity (DOCS) to $37 from $62 and keeps a Buy rating on the shares. The company posted a strong Q3 relative to consensus, but the y/y growth in Q4 guide at 4% fell short of broader investor expectations as customers deployed a lower portion of their annual budgets upfront, and deal execution was delayed, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DOCS:
- Doximity price target lowered to $34 from $46 at Goldman Sachs
- Doximity price target lowered to $49 from $65 at Morgan Stanley
- Doximity price target lowered to $30 from $55 at Evercore ISI
- Doximity price target lowered to $25 from $45 at BMO Capital
- Doximity price target lowered to $50 from $80 at BTIG